Literature DB >> 14658986

Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy.

Andrew A Nierenberg1, Timothy J Petersen, Jonathan E Alpert.   

Abstract

Major depressive disorder is a chronic disorder, frequently characterized by relapses and recurrences. One of the major risk factors for additional episodes of depression is the presence of residual symptoms that persist after a depressive episode ends; these residual symptoms tend to progress to another depressive episode. Although relapse or recurrence may be prevented with long-term pharmacotherapy, this approach is recommended only for patients at high risk of relapse or recurrence. Patients not at high risk who are effectively treated to full remission have a substantially lower risk of developing another depressive episode. In addition, psychotherapy, alone or combined with medication, has been shown to be effective in preventing further episodes of depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14658986

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Centering prayer as an alternative to mindfulness-based cognitive therapy for depression relapse prevention.

Authors:  Joshua J Knabb
Journal:  J Relig Health       Date:  2012-09

2.  Racial/ethnic differences in the association between obesity and major depressive disorder: findings from the Comprehensive Psychiatric Epidemiology Surveys.

Authors:  Amelia R Gavin; Tessa Rue; David Takeuchi
Journal:  Public Health Rep       Date:  2010 Sep-Oct       Impact factor: 2.792

3.  A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.

Authors:  Thomas Shiovitz; William M Greenberg; Changzheng Chen; Giovanna Forero; Carl P Gommoll
Journal:  Innov Clin Neurosci       Date:  2014-01

Review 4.  The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Authors:  Ricardo Moreira
Journal:  Clin Drug Investig       Date:  2011-10-19       Impact factor: 2.859

5.  The prevalence and correlates of depressive symptoms among adolescent mothers: results from a 17-year longitudinal study.

Authors:  Amelia R Gavin; Taryn Lindhorst; Mary Jane Lohr
Journal:  Women Health       Date:  2011-08-31

6.  The association between obesity, depression, and educational attainment in women: the mediating role of body image dissatisfaction.

Authors:  Amelia R Gavin; Greg E Simon; Evette J Ludman
Journal:  J Psychosom Res       Date:  2010-07-03       Impact factor: 3.006

7.  Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity.

Authors:  Andrew D Krystal; W Vaughn McCall; Maurizio Fava; Hadine Joffe; Claudio N Soares; Holly Huang; Todd Grinell; Jacqueline Zummo; William Spalding; Randall Marshall
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-05

8.  When does depression become a disorder? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds.

Authors:  Jerome C Wakefield; Mark F Schmitz
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

Review 9.  Disruption of Neural Homeostasis as a Model of Relapse and Recurrence in Late-Life Depression.

Authors:  Carmen Andreescu; Olusola Ajilore; Howard J Aizenstein; Kimberly Albert; Meryl A Butters; Bennett A Landman; Helmet T Karim; Robert Krafty; Warren D Taylor
Journal:  Am J Geriatr Psychiatry       Date:  2019-08-07       Impact factor: 4.105

10.  Maternal depressive symptoms, depression, and psychiatric medication use in relation to risk of preterm delivery.

Authors:  Amelia R Gavin; Claudia Holzman; Kristine Siefert; Yan Tian
Journal:  Womens Health Issues       Date:  2009 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.